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Abstract
Background: Benzo[a]pyrene (BaP) is a widespread environmental genotoxic carcinogen that damages DNA by
forming adducts. This damage along with activation of the aryl hydrocarbon receptor (AHR) induces complex
transcriptional responses in cells. To investigate whether human cells are more susceptible to BaP in a particular
phase of the cell cycle, synchronised breast carcinoma MCF-7 cells were exposed to BaP. Cell cycle progression
was analysed by flow cytometry, DNA adduct formation was assessed by
32P-postlabeling analysis, microarrays of
44K human genome-wide oligos and RT-PCR were used to detect gene expression (mRNA) changes and Western
blotting was performed to determine the expression of some proteins, including cytochrome P450 (CYP) 1A1 and
CYP1B1, which are involved in BaP metabolism.
Results: Following BaP exposure, cells evaded G1 arrest and accumulated in S-phase. Higher levels of DNA damage
occurred in S- and G2/M- compared with G0/G1-enriched cultures. Genes that were found to have altered
expression included those involved in xenobiotic metabolism, apoptosis, cell cycle regulation and DNA repair. Gene
ontology and pathway analysis showed the involvement of various signalling pathways in response to BaP
exposure, such as the Catenin/Wnt pathway in G1, the ERK pathway in G1 and S, the Nrf2 pathway in S and G2/M
and the Akt pathway in G2/M. An important finding was that higher levels of DNA damage in S- and G2/M-
enriched cultures correlated with higher levels of CYP1A1 and CYP1B1 mRNA and proteins. Moreover, exposure of
synchronised MCF-7 cells to BaP-7,8-diol-9,10-epoxide (BPDE), the ultimate carcinogenic metabolite of BaP, did not
result in significant changes in DNA adduct levels at different phases of the cell cycle.
Conclusions: This study characterised the complex gene response to BaP in MCF-7 cells and revealed a strong
correlation between the varying efficiency of BaP metabolism and DNA damage in different phases of the cell
cycle. Our results suggest that growth kinetics within a target-cell population may be important determinants of
susceptibility and response to a genotoxic agent.
Background
Chemical carcinogens that act by a genotoxic mechan-
ism exert their biological effects through damaging
DNA. This damage can be manifested in several forms,
including single or double strand breaks, apurinic sites
and covalent modification of the bases. Some chemical
carcinogens such as benzo[a]pyrene (BaP), which is a
representative of the class of polycyclic aromatic hydro-
carbons (PAHs), are thought to cause cancer through
covalent binding of their reactive metabolites to DNA,
forming DNA adducts [1-3]. BaP-7,8-diol-9,10-epoxides
(BPDE), the ultimate carcinogenic metabolites of BaP,
react predominantly with the N
2 position of guanine
residues and to a lesser extent with the N
6 position of
adenine residues in DNA [4].
In mammalian cells BaP binds to the aryl hydrocarbon
receptor (AHR), which is a cytosolic ligand-activated
transcription factor that functions as a sensor of extra-
cellular signals and environmental stresses affecting cell
growth and development. AHR controls the expression
of genes coding for xenobiotic-metabolising enzymes
such as cytochrome P450s (CYPs), UDP-glucuronosyl-
transferase UGT1A6, NAD(P)H:quinone oxidoreduc-
tase-1 (NQO1), aldehyde dehydrogenase (ALDH3A1),
and several glutathione-S-transferases [5]. It is also
involved in regulation of development and in the control * Correspondence: hamza.hamouchene@icr.ac.uk
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to hypoxia [6].
More recently it has also become evident that AHR
has another function, namely in controlling cell cycle
progression. For instance, high-affinity AHR ligands,
such as some PAHs, cause a wide range of cell-cycle
perturbations, including G0/G1 arrest or its evasion
(the stealth property) [7], G2/M arrest, S-phase accu-
mulation, diminished capacity for DNA replication and
inhibition of cell proliferation [8]. These perturbations
have been documented in several gene expression pro-
filing studies. Previously we have used microarray tech-
nology to analyse the transcriptomes of several human
cell lines exposed to BaP [9,10]. Altered expression of
a number of genes involved in cell cycle regulation
were identified, including C D K N 1 A ,M A K ,B T G 2 ,
CCNG1 and E2F6. Other studies have shown that up-
regulated AHR-dependent activation of CYP1A1 fol-
lowing BaP exposure may be dependent on the cell-
cycle phase [11-13], suggesting that the phase of the
cell cycle may be critical to some of the effects of BaP
on human cells.
In this study, we investigated whether cells are more
susceptible to a genotoxic carcinogen, namely BaP, at
particular phases of the cell cycle and, if so, to elucidate
the processes involved. DNA microarrays were used to
examine changes in gene expression throughout the cell
cycle in synchronised human breast carcinoma MCF-7
cells following exposure to non-cytotoxic concentrations
of BaP. Cell cycle phase-specific changes in gene expres-
sion profiles resulting from carcinogen exposure have
identified novel genes and pathways potentially involved
in the carcinogenic process. To strengthen the process
of identifying target genes, gene expression data were
compared to other biological parameters, including
DNA adduct formation, determined by
32P-postlabelling
analysis, and cell cycle progression, measured by FACS
analysis.
Results
Cell cycle progression
In initial experiments, the optimum time of treatment
with BaP was determined to be 12 h. This gave suffi-
cient time for cells to metabolise BaP to DNA-binding
reactive intermediates, but minimised the extent to
which untreated synchronised cells altered their cell-
cycle phase composition. In the case of G0/G1 enrich-
ment, cells will start exiting the quiescent state (G0) and
entering G1 soon after adding the serum back to the
medium. Thus, from now on, these cells are referred to
as G1-enriched. In previous work, the treatment concen-
tration of 2.5 μM was found to induce DNA adduct for-
mation in MCF-7 cells within a linear dose-response
range [9].
G1-enriched cultures (serum deprivation for 48 h) did
not differ significantly in the proportions of cells in dif-
ferent phases after treatment for 12 h with BaP com-
pared with DMSO-treated controls (Figure 1A and
Additional file 1A). Cells were progressing through the
cell cycle and started entering S and G2/M phases by
the end of the treatment. We did not observe a G1
arrest after BaP treatment.
Exposure of S-enriched cultures (18 h after 48 h of
serum deprivation) to BaP evoked dramatic alterations
in cell cycle distribution with an increase of the fraction
of cells in S-phase (59.6 vs 32.4, P <0 . 0 0 1 ;F i g u r e1 B
and Additional file 1B). The percentage of cells in G2/
M-phase was significantly lower than in control cultures
(P < 0.001).
Similarly, BaP treatment of G2/M-enriched cultures
(24 h treatment with 1 μg/mL aphidicolin followed by
12 h 0.25 μM colchicine) increased the proportion of
cells in S-phase (17.6 vs 11.2, P = 0.0045; Figure 1C and
Additional file 1C).
DNA damage in synchronised MCF-7 cells
BaP-DNA adduct formation was determined by the
32P-
postlabelling method. Cells enriched in G1, S and G2/M
that were exposed to BaP for 12 h showed different
levels of DNA adducts (Figure 2A). Levels of adducts in
the S- and G2/M-enriched cultures were 3 to 4-fold
higher than levels observed in G1-enriched cultures.
When cells were treated with BPDE for 12 h, the reac-
tive metabolite of BaP, similar levels of DNA adducts
were formed in all cultures regardless of cell-cycle phase
(Figure 2B). Since BPDE does not require metabolic
activation to bind to DNA, and has a short half-life in
aqueous environments, this result suggests that the dif-
ferences observed with BaP are the consequence of dif-
ferent capacities to metabolically activate BaP at
different stages of the cell cycle.
BaP-induced gene expression changes by microarray
analysis
cDNA microarray analysis was carried out on synchro-
nised cultures of MCF-7 cells enriched in G1, S and G2/
M phases and exposed to 2.5 μM BaP for 12 h.
Condition clustering and principal component analysis
(PCA) revealed that exposure to BaP resulted in expres-
sion profiles more distinguishable by cell-cycle phase
than by treatment (Figure 3).
Differentially expressed genes in each enriched culture
were identified using Student’s t-test and a cut-off of
1.5-fold change in expression. This resulted in 417
genes in G1-, 189 genes in S-, and 519 genes in G2/M-
enriched cultures (Figure 4). 16 genes were shared
between all phases (Additional file 2), 11 between G1
and S only (Additional file 3), 37 between G1 and G2/M
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only (Additional file 5). However, the majority of modu-
lated genes were cell-cycle specific (Figure 4).
Functional annotations of BaP-modulated genes
In order to find biological processes significantly over-
represented in the gene lists generated by statistical ana-
lysis, overlay of gene ontology information was carried
out using the Gene Ontology (GO) function within
GeneSpring. Biological themes that occurred in response
to BaP through the cell cycle were thereby identified.
The majority of functions identified indicate that the
transcriptional response to BaP in MCF-7 cells in differ-
ent phases is complex, with a large number of biochem-
ical and molecular pathways being affected (Table 1).
In G1, genes involved in macromolecule metabolism
were over-represented by four functional groups: macro-
molecule biosynthesis (10%), positive regulation of meta-
bolism (5%) and transcription (4%), and amino acid
transport (2%). These genes are involved in RNA tran-
scription and protein synthesis and code for several
ribosomal proteins (for example RPS10, RPS14,a n d
RPS15A), solute carriers (SLC6A6, SLC7A11 and
SLC6A14), and regulators of transcription (ATF4, JUN,
EGR1, RSF and TRERF1). Other modulated genes
belonged to cell differentiation (11%) and cell prolifera-
tion (8%) functional groups.
In S-phase, cell proliferation functional groups (7%)
were again identified including the genes BTG2, BTG3,
GAS8 and HDAC4.O ft h e s e ,BTG2 and BTG3 (both
up-regulated) belong to a family of anti-proliferative
genes. Genes involved in PAH metabolism were also
over-represented and these included CYP1B1, AKR1C1,
ALDH1A3 and UGT1A6.
In G2/M-phase, the largest functional groups identi-
fied were regulation of nucleic acid metabolism (24%)
and regulation of transcription (22%), followed by cell
differentiation (10%) and cell cycle (10%). Cell cycle reg-
ulation genes induced by BaP included NPM1, NBN,
FHIT, CABLES2, ATF5, PCAF, CCNG1, RGC32, SESN1
and BAX. Signal transduction genes were represented by
s e v e r a lf u n c t i o n a lg r o u p ss u c ha ss m a l lG T P a s e -
mediated signal transduction (6%), MAPKKK cascade
(3%) and stress-related protein kinase signalling pathway
(2%).
Pathway analysis of BaP-modulated genes
The generated gene lists from GeneSpring were sub-
mitted to Ingenuity Pathway Analysis (IPA) and several
interesting pathways and genes were revealed. Seven
selected networks are presented here (Figure 5, 6 and 7
with Additional file 6); they are the top two scoring net-
works in each enriched culture and a third one for G2/
M-enriched cultures. This selection was based on the
A
B
C
12 h BaP treatment of S-enriched cells
Before treatment S- 12 h DMSO S- 12 h BaP
0
20
40
60
80
G0/G1
S
G2/M
Conditions
c
e
l
l
 
p
e
r
c
e
n
t
a
g
e
12 h BaP treatment of G2/M-enriched cells
Before treatment G2/M- 12 h DMSO G2/M- 12 h BaP
0
20
40
60
80
100
G0/G1
S
G2/M
Conditions
c
e
l
l
 
p
e
r
c
e
n
t
a
g
e
12 h BaP treatment of G1-enriched cells
Before treatment G1- 12 h DMSO G1- 12 h BaP
0
20
40
60
80
G0/G1
S
G2/M
Conditions
c
e
l
l
 
p
e
r
c
e
n
t
a
g
e
Figure 1 BaP delays escape from S-phase. A-M C F - 7c e l l sw e r e
synchronised in G0/G1-phase by serum-deprivation for 48 hours,
after which cells were exposed for 12 h to BaP (2.5 μM) or DMSO.
B- MCF-7 cells were enriched in S-phase by serum-deprivation for
48 h, then left to grow for 18 h, after which they were treated by
either BaP (2.5 μM) or DMSO for 12 h. C- MCF-7 cells were
synchronised in G2/M-phase by exposing them to aphidicolin (1 μg/
mL) for 24 h followed by colchicine (0.25 μM) for 12 h.
Subsequently, they were released into media containing either BaP
(2.5 μM) or DMSO for 12 h. Cell cycle distribution was examined by
flow cytometry. The profiles are representative of three independent
experiments.
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Page 3 of 16ranking score within IPA, where networks with the
highest number of significant changes rank highest in
the list (a list of the top five scoring networks in each
enriched culture is presented as supplementary data in
Additional file 7). Several biological processes and sig-
nalling pathways were shown to be at the centre of BaP-
modulation, as described below.
G1-phase (Figure 5, Network A and B) Network 5A
relates to the Catenin/Wnt pathway, which has a crucial
role in embryonic development. Its deregulation can
induce disease, most importantly cancer. One important
gene in this pathway is CTNNB1, which stabilises b-cate-
nin, a cytoplasmic protein that translocates into the
nucleus and activates downstream genes such as MYC and
cyclin D1, both of which regulate cell proliferation [14].
Network 5B involves mainly the JUN, EGR1 and ERK
pathway. JUN, which is up-regulated in both G1-a n dS-
phases, is an oncogene and a transcription factor that
plays a role in the regulation of normal cell cycle pro-
gression [15]. EGR1 is another transcription factor that
was up-regulated at the mRNA level in our study. It is
at the crossroads of many signalling cascades. Many
functions have been attributed to this protein, in parti-
cular its involvement in the control of cell growth, sur-
vival and transformation [16].
S-phase (Figure 6, Network A and B) JUN is again the
focus of Network 6A and it is linked to several other
genes, for example GDF15 and ATF3,b o t ho fw h i c h
were up-regulated in the present study.
ATF3 is a member of the ATF/cyclic AMP response
element-binding family of transcription factors. It has
been proposed that it has a dichotomous role in cancer
development by promoting or suppressing apoptosis and
proliferation [17]. GDF15 is a member of the transform-
ing growth factor B (TGFB) superfamily that regulates
tissue differentiation and maintenance. It is also a tran-
scriptional target of p53 [18]. Another interesting gene
s h o w ni nt h i sn e t w o r ki sNFB, which promotes cell
survival.
Network 6B shows mainly molecules that are involved
in oxidative stress; NFE2L2 (NRF2) is induced in
response to reactive oxygen species such as hydrogen
peroxide. NRF2 plays a major role in the protective
mechanism against xenobiotics capable of damaging
DNA and initiating carcinogenesis. It is a cellular sensor
of chemical- and radiation-induced oxidative and elec-
trophilic stress, and a nuclear transcription factor that
controls the expression and coordinated induction of a
battery of defensive genes encoding detoxifying enzymes
and antioxidant proteins. One of these proteins is
NQO1 [19], which is mentioned in the Introduction.
G2/M-phase (Figure 7, Network A, B and C) Network
7A involves two pathways, Akt and apoptosis. Akt is a
serine/threonine protein kinase that, when activated,
plays a key role in mediating signals for cell growth, cell
survival (anti-apoptotic), cell-cycle progression, differen-
tiation, transcription, translation, and glucose metabo-
lism. Recent advances in studying Akt signalling have
Figure 2 DNA adduct levels in synchronised MCF-7 cells. Cell were synchronised in G0/G1, S and G2/M phases with different methods, after
which they were exposed to 2.5 μM BaP or 0.5 μM BPDE for 12 h. DNA was isolated with a standard phenol/chloroform method and DNA
adducts were assessed by the
32P-postlabelling method. Results were expressed as DNA adducts/10
8 nucleotides.
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Figure 3 Cell cycle effects on microarray results. A- Hierarchical clustering of genes in different conditions; B- Principal component analysis
(PCA). Both methods were performed in GeneSpring on a list of genes that had good confidence measurement and revealed a cell cycle
response in gene expression profiles. Before BaP (2.5 μM) treatment for 12 h, MCF-7 cells were synchronised in different phases of the cell cycle.
In hierarchical clustering (A), red colour denotes up-regulation and green denotes down-regulation. In PCA analysis (B), squares with black dots
denote BaP-treated samples.
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Page 5 of 16uncovered important roles in G2/M transition of the cell
cycle where Akt activity is highest [20]. The NRF2 path-
way is again central to Network 7B, which shows several
genes involved in oxidative stress mechanisms such as
NFE2L2, GSTM1, SLC7A11, and AHRR.
Network 7C was selected to be shown here because it
has the important tumour suppressor TP53 at its centre
along with several of its targets, confirming results
obtained by gene ontology analysis. ASPM participates
in the normal mitotic spindle function while MBNL2
belongs to the muscleblind family that regulates alterna-
tive splicing. CABLES2 is a pro-apoptotic factor involved
in p53-dependent or p53-independent apoptosis [21]
while Scaper is a cyclin A-interacting protein that regu-
lates cell cycle progression at the G/S and G2/M check-
points [22].
BaP-induced gene expression changes by RT-PCR
RT-PCR is a more sensitive and specific measure of
gene expression and was used to validate a number of
key expression changes and to determine the reliability
of the microarrays. Genes were selected for RT-PCR
validation on the basis of: a) GeneSpring statistical
analysis, b) gene ontology analysis and c) pathway
analysis.
Genes validated by RT-PCR are shown in Table 2. In
t h em a j o r i t yo fc a s e st h e r ew a sag o o dc o r r e l a t i o n
between RT-PCR and microarray results, RT-PCR being
more sensitive; expression ratios were generally underes-
timated by microarray analysis. For CYP1A1, the corre-
lation between the two methods was very low; no clear
change in this transcript was evident from the microar-
rays, whereas RT-PCR identified strong induction in all
phases ranging from 74-fold in G2/M-enriched cultures
to over 1800-fold in S-enriched cultures (Figure 8). The
failure of the microarrays to identify this gene expres-
sion change may be a result of very low basal levels of
this transcript in this cell line, such that even if strongly
induced, the microarrays are not sensitive enough to
detect it. Another explanation could be the quality and
specificity of the probe sequence in the array.
Protein expression
There was a clear induction of both CYP1A1 and
CYP1B1 proteins after BaP exposure in all phases, but
to a greater extent in S- and G2/M- than in G1-enriched
cultures (Figure 9). Band quantification showed that
t h e r ew a sa1 . 5 - f o l dh i g h e rl e v e lo fC Y P 1 B 1i nS- and
G2/M- than in G1-enriched cultures after BaP treat-
ment. Similarly, the amount of CYP1A1 protein after
BaP exposure was 5 to 6-fold higher in S-a n dG2/M-
than in G1-enriched cultures. These findings correlate
strongly with levels of DNA adducts seen in the differ-
ent phases. There was a down-regulation of AHR after
BaP treatment, as the protein levels were lower by 2-
fold in BaP-treated compared to DMSO control cells in
all enriched cultures.
A number of TP53-regulated genes were modulated in
response to BaP exposure at: a) the microarray level:
STMN1 in G1 only; GDF15 and BTG2 in S only; PCAF,
BAX, SESN1, ASPM, MBNL2, CABLES2 and Scaper in
G2/M only; c-Jun and BTG3 in G1 and S; HINT1 and
RGC32 in G1 and G2/M;b )t h eR T - P C Rl e v e l :
CDKN1A, GDF15,a n dRGC32 in all phases. Other
genes that regulate TP53 activity, such as MDM4 and
NPM1, were also modulated by BaP.
However, as expected, induction of TP53 gene expres-
sion was not observed on the microarrays and this was
confirmed by RT-PCR. Therefore, p53 protein levels
were assessed by Western blotting in order to confirm
accumulation of this tumour suppressor in response to
the BaP in different phases of the cell cycle (Figure 9).
An increase in p53 protein was observed in MCF-7 cells
after exposure to BaP in all phases with considerably
more protein in G2/M-enriched cultures, underlying its
significant role in the G2/M checkpoint. These profiles
of p53 protein activation are similar to those of its direct
target CDKN1A (p21), except that there was no induc-
tion in S-enriched cultures (Figure 9).
Discussion
Microarray technology is a powerful tool for identify-
ing gene expression patterns that are reflective of the
response of cells to carcinogen exposure [23-25], and
can be informative of mechanisms of action [26,27].
U s i n gt h i st e c h n o l o g yw eh a v ei n v e s t i g a t e dw h e t h e r
human cells are more susceptible to the environmen-
tal carcinogen BaP at particular phases of the cell
Figure 4 Venn diagram of the gene lists in different phases.
Only genes that exhibited 1.5-fold or greater change after BaP
treatment are shown. The gene lists represent expression profiles of
MCF-7 cells synchronised in different phases of the cell cycle.
Although there was overlap of the expression profiles between the
phases, the majority of the changes were cell-cycle dependent.
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Page 6 of 16Table 1 Biological processes significantly affected (p < 0.05) and over-represented after BaP treatment in
synchronised MCF-7 cells in G0/G1, S, and G2/M as determined by Gene Ontology (GO) analysis within GeneSpring
software
Biological Process % of Genes in List p-Value
G1-enriched cells
GO:7275: development 26.4 1.50E-03
GO:9653: morphogenesis 11.8 1.60E-02
GO:30154: cell differentiation 11.4 1.20E-02
GO:9059: macromolecule biosynthesis 10 1.10E-02
GO:8283: cell proliferation 8.6 1.90E-02
GO:31325: positive regulation of cellular metabolism 5 3.10E-02
GO:45941: positive regulation of transcription 4.1 4.90E-02
GO:45321: immune cell activation 3.2 2.30E-02
GO:51606: detection of stimulus 2.3 4.00E-03
S-enriched cells
GO:50789: regulation of biological process 42.7 1.30E-02
GO:42127: regulation of cell proliferation 7.3 2.10E-02
GO:40007: growth 5.5 1.70E-02
GO:42592: homeostasis 5.5 4.10E-02
GO:45944: positive regulation of transcription from RNA polymerase II promoter 3.6 2.20E-02
GO:7420: brain development 2.7 4.60E-02
GO:9065: glutamine family amino acid catabolism 1.8 7.20E-03
GO:6805: xenobiotic metabolism 1.8 2.10E-02
GO:9266: response to temperature stimulus 1.8 2.10E-02
GO:7157: heterophilic cell adhesion 1.8 2.20E-02
GO:6664: glycolipid metabolism 1.8 2.70E-02
GO:30203: glycosaminoglycan metabolism 1.8 5.00E-02
GO:35026: leading edge cell differentiation 0.9 5.60E-03
GO:42268: regulation of cytolysis 0.9 5.60E-03
GO:46399: glucuronate biosynthesis 0.9 1.10E-02
GO:16264: gap junction assembly 0.9 1.70E-02
GO:6975: DNA damage induced protein phosphorylation 0.9 1.70E-02
GO:48246: macrophage chemotaxis 0.9 3.30E-02
G2/M-enriched cells
GO:19219: regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism 23.9 1.40E-03
GO:6355: regulation of transcription, DNA-dependent 21.8 1.80E-02
GO:30154: cell differentiation 10.6 1.10E-02
GO:7049: cell cycle 9.9 2.70E-04
GO:7264: small GTPase mediated signal transduction 6.3 6.90E-03
GO:9888: tissue development 4.2 1.30E-02
GO:16337: cell-cell adhesion 3.5 6.20E-03
GO:165: MAPKKK cascade 2.8 1.70E-02
GO:31098: stress-activated protein kinase signaling pathway 1.8 2.30E-03
GO:8624: induction of apoptosis by extracellular signals 1.4 3.70E-02
GO:42551: neuron maturation 1.4 3.00E-03
GO:6986: response to unfolded protein 1.4 1.10E-02
GO:51259: protein oligomerization 1.4 2.60E-02
GO:9266: response to temperature stimulus 1.1 1.50E-02
Genes over-represented had an expression change of at least 1.5-fold.
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involved. The resulting gene expression profiles were
related to other phenotypic measures of BaP expo-
sure such as DNA damage and cell cycle distribution
to further our biological understanding of BaP
carcinogenesis.
We found that BaP induced more DNA damage in
synchronised MCF-7 cells enriched in S- and G2/M-
phases than in G1, which indicates that BaP is metabo-
lised with varying efficiency at different stages of the cell
cycle. This conclusion is supported by the fact that
DNA damage induced by BPDE -which modifies DNA
without further metabolism-, was not cell cycle
Figure 5 Ingenuity Pathway Analysis (IPA) on genes modulated
by BaP in G1-enriched MCF7 cell cultures. Gene lists of 1.5-fold
differentially expressed genes in different phases were imported to
IPA software, which revealed the involvement of several pathways
and genes in the response to BaP. Two networks are shown here.
Red colour denotes up-regulation and green colour denotes down-
regulation. The IPA legend is shown in Additional file 6.
Figure 6 Ingenuity Pathway Analysis (IPA) on genes modulated
by BaP in S-enriched MCF-7 cell cultures. Gene lists of 1.5-fold
differentially expressed genes in different phases were imported to
IPA software, which revealed the involvement of several pathways
and genes in the response to BaP. Two networks are shown here.
Red colour denotes up-regulation and green colour denotes down-
regulation. The IPA legend is shown in Additional file 6.
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protein expression of xenobiotic metabolising enzymes
further supported this hypothesis. Indeed, CYP1A1
mRNA measured by RT-PCR was almost 20-fold higher
in S-phase than in G1 and G2/M. CYP1B1 mRNA fol-
lowed the same pattern with a 2-fold higher induction
in S-phase. Moreover, comparison between the levels of
CYP1A1 in different phases revealed more mRNA in S-
and G2/M-enriched cultures. The same pattern was
observed at the protein level for CYP1A1 and CYP1B1.
These findings correlate well with the levels of BaP-
DNA adducts at each phase of the cell cycle, consistent
with the role of CYP1A1 and CYP1B1 in the metabolic
activation of BaP to BPDE.
Previously, Jiao et al. [11] reported an up-regulation of
CYP1A1 mRNA of > 100-fold in BaP-treated S-enriched
MCF-7 cultures, while up-regulation in G1- and G2/M-
enriched cultures occurred to a significantly lesser
extent. Consistent with this, they also reported higher
levels of DNA damage in the form of DNA single strand
breaks and BaP-DNA adducts in S-enriched cultures.
However, it is not the extent of induction that matters
but the actual levels (absolute amounts) of mRNA and
protein, because an apparently very strong induction
could be due simply to very low basal levels. Moreover,
Jiao and coworkers’ BaP treatment was for 24 h, a dura-
tion that is long enough for the cells to progress to
another phase of the cell cycle. In another study, Santini
et al. [13] showed that within 3 h of TCDD exposure
late G1/early S-phase U937 human leukaemic monocyte
lymphoma cells had 1.4- and 3-fold higher CYP1A1
mRNA levels than asynchronous/early G1 and G2/M
cultures, respectively. In contrast, we found that the
absolute mRNA levels of CYP1A1 and the protein levels
of both CYP1A1 and CYP1B1 were actually higher in S-
and G2/M-enriched cultures. AHR down-regulation at
the protein level in all enriched cultures was the result
of suppressing AHR signalling by rapid proteosomal
degradation. Ligand-dependent receptor activation is
well established, and several mechanisms capable of sup-
pressing prolonged AHR signalling have been identified.
These include rapid receptor degradation, the action of
an AHR Repressor protein (AHRR), and agonist deple-
tion through an enzymatic negative feedback loop [28].
AHR activation independent of agonist binding in mam-
malian systems has been proposed, but evidence for it is
n o ty e tc o n c l u s i v e .C h a n ga n dP u g a[ 2 9 ]r e p o r t e dt h a t
AHR-dependent effects on cell proliferation could be
dissociated from exogenous ligand binding. In another
study, cell density, but not cell cycle, was shown to
influence the intracellular distribution of AHR [30].
However, neither study established the absence of an
endogenous ligand responsible for receptor activity.
Figure 7 Ingenuity Pathway Analysis (IPA) on genes modulated
by BaP in G2/M-enriched MCF-7 cell cultures. Gene lists of 1.5-
fold differentially expressed genes in different phases were
imported to IPA software, which revealed the involvement of
several pathways and genes in the response to BaP. Three networks
are shown here. Red colour denotes up-regulation and green colour
denotes down-regulation. The IPA legend is shown in Additional
file 6.
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Page 9 of 16Preliminary experiments have indicated that there
are no differences in BaP-DNA adduct formation
between G0- and G1-enriched MCF-7 cultures (data
not shown). Therefore, adduct levels in G0- are lower
than S-a n dG2/M-enriched cultures. G0 cells are
quiescent i.e. not cycling, as is the case with many cell
types in mammalian tissues. Interpreting the adduct
data in the light of this information could point to a
difference in susceptibility to genotoxic carcinogens
between proliferating (cycling cells that go beyond G1
Table 2 A summary of gene expression changes induced by BaP in MCF7 cells using microarray and RT-PCR analysis
Change in G1 Change in S Change in G2/M
Gene Symbol Biological function RT-PCR Microarrays RT-PCR Microarrays RT-PCR Microarrays
CYP1A1 Xenobiotic metabolism ↑ 91.5-fold ─ ↑ 1866.8-fold ─ ↑ 73.7-fold ─
CYP1B1 Xenobiotic metabolism ↑ 19-fold ↑ 2.7-fold ↑ 40.4-fold ↑ 3.2-fold ↑ 21.9-fold ↑ 2.3-fold
GDF15 Cell differentiation ↑ 11.2-fold ─ ↑ 22.5-fold ↑ 8.9-fold ↑ 2-fold ─
TIPARP PARP family ↑ 5.5-fold ─ ↑ 5.8-fold ↑ 2.9-fold ↑ 6-fold ↑ 4.7-fold
JUN Cell proliferation ↑ 5.5-fold ↑ 1.8-fold ↑ 5.1-fold ↑ 3.6-fold ──
p21 cell cycle checkpoints ↑ 3.2-fold ─ ↑ 6.6-fold ── ─
RASAL1 Ras regulator ↑ 3.4-fold ─ ↑ 2.8-fold ↑ 3.3-fold ─ ↓ 2.8-fold
RGC32 Cell cycle control ↑ 2.9-fold ↑ 1.6-fold ↑ 2.3-fold ─ ↑ 2.3-fold ↑ 1.5-fold
ALDH1A3 Xenobiotic metabolism ↑ 1.7-fold ─ ↑ 4.2-fold ↑ 4.3-fold ↑ 2.4-fold ─
DLX2 Development ↑ 1.5-fold ─ ↑ 4.8-fold ↑ 5-fold ↑ 2.5-fold ↑ 3.3-fold
CEBPA Mitotic growth arrest ↑ 1.7-fold ───↑ 1.5-fold ↑ 1.7-fold
NRF2 Oxidative stress ↑ 1.5-fold ───↑ 1.6-fold ↑ 1.6-fold
ATF3 Transcription Factor ↑ 3-fold ─ ↑ 6.1-fold ↑ 4.5-fold ─
DNAJB4 Oxidative stress ↑ 2.2-fold ─ ↑ 1.6-fold ↑ 1.9-fold ─ ↑ 1.5-fold
Bax Apoptosis ↑ 1.5-fold ─ ↑ 1.6-fold ── ↑ 1.6-fold
SPRY4 MAPK signalling ── ─ ↑ 4.5-fold ↑ 1.7-fold ─
GSTT2 Xenobiotic metabolism ↑ 2.8-fold ↑ 1.7-fold ─── ─
CABLES2 Apoptosis ── ─ ─ ─↑ 2.3-fold
PTGER4 T-cell factor signalling ─ ↑ 2.7-fold ↑ 1.5-fold ── ↑ 2.2-fold
BBC3 Apoptosis ── ↑ 2.1-fold ↑ 5-fold ─ ↑ 1.9-fold
EGR1 Cell growth and proliferation ↑ 6.7-fold ↑ 2.7-fold ↑ 2.5-fold ── ─
CTNNB1 Cell adhesion ↑ 1.5-fold ↑ 2.25-fold ─── ─
PLK3 Cell cycle control ── ↑ 2.5-fold ↑ 3.4-fold ──
AFF4 Transcription Elongation ── ─ ↓ 2.6-fold ↓ 1.5-fold ↓ 6.2-fold
ZBRK1 DNA damage response ── ─ ↓ 4.7-fold ──
DKK1 Wnt/Catenin ↓ 7-fold ↓ 3.1-fold ↓ 2.8-fold ─ ↓ 2.4-fold ─
KAT2B Transcription regulation ↓ 4.6-fold ─ ↓ 3-fold ─ ↓ 6.5-fold ↓ 1.7-fold
RASGRP1 Ras signalling ↓ 3.8-fold ↓ 1.5-fold ↓ 2.2-fold ─ ↓ 6-fold ↓ 2-fold
JMJD2C Histone demethylase ↓ 3.6-fold ─ ↓ 4.5-fold ↓ 2-fold ↓ 3-fold ↓ 1.8-fold
HDAC4 Cell cycle control ↓ 2.1-fold ─ ↓ 2.7-fold ↓ 1.8-fold ↓ 1.8-fold ─
FERMT1 Actin cytoskeleton ↓ 2.1-fold ↓ 6.7-fold ↓ 1.8-fold ─ ↓ 2.5-fold ─
Scaper cell cycle checkpoints ↓ 1.8-fold ↓ 1.5-fold ↓ 1.8-fold ↓ 2-fold ↓ 2.8-fold ↓ 2.2-fold
NPM1 Cell proliferation/Apoptosis ── ─ ─ ─↑ 2.4-fold
YWHAQ Cell cycle control/Apoptosis ── ─ ─ ──
AHR Xenobiotic Metabolism ── ─ ─ ──
p53 Tumour Suppressor ── ─ ─ ──
RFC5 Replication Factor ─ ↑ 1.8-fold ─── ─
Hint1 Apoptosis ─ ↑ 2.2-fold ─── ↑ 1.5-fold
NQO1 Xenobiotic metabolism ─ ↑ 2.2-fold ─── ─
A 1.5-fold cut-off was used. ↑ denotes up-regulation, and ↓ denotes down-regulation.
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Page 10 of 16to S,a n dG2/M) and non-proliferating cells (mainly in
G0).
BaP exposure resulted in an arrest of the cells in S-
phase of the cell cycle in S- and G2/M-enriched cul-
tures, indicating that interruption of DNA synthesis had
occurred. This is in agreement with other studies that
have shown the inhibition of DNA synthesis in response
to BaP [9,31]. The pause in DNA synthesis is probably
due to the intra-S checkpoint, which allows repair
enzymes time to recognize the damaged DNA and to
correct it, avoiding irreversible errors during replication
(i.e. mutations). Alternatively, a permanent growth arrest
or apoptosis can be initiated if damage is too great or
persists for too long [32].
We found that BaP did not activate the G1/S check-
point despite p53 and p21 protein induction in these
phases. The G1 arrest delays DNA damaged cells from
progressing through the cell cycle, avoiding accumula-
tion of mutations and chromosomal aberrations by
means of DNA repair or apoptosis. TP53 and its tran-
scriptional target CDKN1A (p21)c o n t r i b u t et oG1 and
G2 arrest in response to DNA damage to maintain
genomic stability [33]. These responses consist of the
ATM(ATR)/CHK2(CHK1)-p53/MDM2-p21 pathway,
which is capable of sustaining G1 arrest. Phosphoryla-
tion of p53 transcription factor and MDM2 (which nor-
mally binds to p53 and ensures rapid p53 turnover)
results in p53 stabilisation and accumulation. p21, in
turn, inhibits cyclin E(A)/CDK2 and preserves the RB/
E2F pathway in its active, growth-suppressing mode
[32,34,35].
In one study, Khan and Dipple [7] showed that follow-
ing treatment with a range of agents, including metabo-
lites of BaP, G1 arrest does not occur in MCF-7 cells
and other cell lines. They also demonstrated that BPDE
is not effective in arresting MCF-7 cells in G1 in spite
of inducing dose-dependent increases in p53 and p21
[36]. The ability of carcinogens to induce cells to evade
the G1 DNA-damage checkpoint and progress into S-
phase is known as the stealth property. This property
presumably enhances the mutation frequency and
increases the likelihood of malignant changes.
In another study, Jiao et al. [37] investigated the
mechanisms by which BaP accelerates cell cycle progres-
sion (G1/S transition) and induces cell proliferation in
human embryo lung fibroblasts. They also found that c-
Jun activation (by phosphorylation) by p53-dependent
PI-3K/Akt/ERK pathway might be responsible for BaP-
induced cell cycle alterations. Interestingly, JUN mRNA
was up-regulated by BaP in our study in both G1-a n d
S-enriched cultures. In addition to that, our pathway
analysis showed it to be significantly involved in Net-
work 5B (G1-enriched cells) and Network 6A (S-
enriched cells).
Gene Ontology analysis revealed several over-repre-
sented biological themes after BaP exposure. These
include cell differentiation, cell proliferation, cell cycle
regulation and xenobiotic metabolism. In G1-enriched
cultures, some modulated genes belonged to cell differ-
entiation (11%) and cell proliferation (8%) functional
groups. One of these genes is BTG3 (up-regulated),
which has been identified as a DNA damage-inducible
CHK1-modulated gene. As it is a direct p53 target this
emphasises its importance in cell cycle regulation and in
maintaining genome stability [38]. Another example of
modulated genes involved in regulating cell proliferation
CYP1A1 mRNA levels
G1 S G2
0.0
0.5
1.0
1.5
50
100
150 DMSO
BaP
Conditions
C
Y
P
1
A
1
 
E
x
p
r
e
s
s
i
o
n
 
l
e
v
e
l
s
 
(
%
)
Figure 8 Relative CYP1A1 mRNA expression levels in
synchronised MCF7 cells with and without BaP treatment.
mRNA quantification was carried out by RT-PCR. The highest
expressed sample in the RT-PCR was set to 100% and other
samples’ expressions are shown relative to that. Values represent
mean ± SD from 3 determinations.
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Figure 9 Expression of CYP1A1, CYP1B1, AHR, p53, and p21
protein levels in MCF7 cells in different phases of the cell cycle
in response to BaP detected by Western blots. Cells were
treated with DMSO (0.3%) or BaP (2.5 μM) for 12 h. 15 μg protein
was loaded in each lane. b-actin was used as a loading control.
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Page 11 of 16and differentiation is EGR1, which was also revealed by
pathway analysis (Network 5B in G1-enriched cells).
Modulation of the expression of this gene was validated
by RT-PCR and it was shown to be induced in G1-, and
S-enriched cultures. Several xenobiotic metabolism
genes were also modulated by BaP, including CYP1B1,
GSTT2 and NQO1. Detoxification of PAH quinone
metabolites is carried out by NAD(P)H:quinone oxidore-
ductase encoded by NQO1 [39], which is also required
for p53 stabilisation in response to DNA damage [40].
Glutathione S-transferase T2 (GSTT2) is involved in cel-
lular defence against toxic and carcinogenic electrophilic
compounds by conjugation of reduced glutathione to
hydrophobic electrophiles [41], so it was a logical find-
ing that GSTT2 was up-regulated in response to BaP
exposure.
Pathway analysis revealed the activation of the Cate-
nin/Wnt pathway (Network 5A) in the response to BaP
exposure. Consistent with this, RT-PCR analysis showed
that DKK1 (a Wnt antagonist) was down-regulated (by
7-fold) in G1-enriched cultures and CTNNB1 was up-
regulated (by 1.4-fold) in the same cultures.
In S-phase, cell proliferation and apoptosis genes such
as BTG2 and HDAC4 were also differentially expressed.
Previously, our team showed that BTG2 was up-regulated
by BaP and BPDE at different time points in MCF-7 cells
[9,10]. Its expression was also shown to be induced by
genotoxic stress through a p53-dependent mechanism
[42]. HDAC4, which encodes a histone deacetylase that
represses transcription and regulates differentiation, was
down-regulated in our experiments [43]. Differentially
expressed genes involved in PAH metabolism included
CYP1B1, AKR1C1, ALDH1A3 and UGT1A6. CYP1B1
(also induced in G1-a n dG2/M-enriched cultures)
encodes a member of the CYP superfamily of monooxy-
genases and is involved in the metabolic activation of
BaP [44,45]. Interestingly, enhanced expression of this
enzyme has been observed in a number of cancers
[46,47] and it has been demonstrated, in experiments
involving CYP1B1-null mice, that it enhances the carci-
nogenicity of 7,12-dimethylbenz[a]anthracene [48].
CYP1B1 has also been found to be up-regulated in pri-
mary human mammary epithelial cells exposed to BaP,
highlighting the importance of this enzyme in BaP meta-
bolism in this tissue [49]. Consistent with previous stu-
dies [9,50], AKR1C1 was also found to be up-regulated
by BaP. It encodes an aldo-keto reductase capable of
metabolising PAH trans-dihydrodiols to o-quinones that
can lead to the formation of DNA adducts and reactive
oxygen species (ROS) [50,51], thus providing another
pathway of PAH genotoxicity. UGT1A6 is involved in
glucuronidation, which is a major pathway for detoxifica-
tion of PAH metabolites [52].
Another interesting gene function category revealed by
the transcriptomic analysis was that of DNA-damage
induced protein phosphorylation, as exemplified by
MAP2K6. This gene encodes a member of the dual spe-
cificity protein kinase family, which functions as a mito-
gen-activated protein (MAP) kinase kinase. MAP
kinases, also known as extracellular signal-regulated
k i n a s e s( E R K s ) ,a c ta sa ni n t egration point for multiple
biochemical signals. This protein phosphorylates and
activates p38 MAP kinase in response to inflammatory
cytokines or environmental stress. As an essential com-
ponent of the p38 MAP kinase signal transduction path-
way, MAP2K6 is involved in many cellular processes
such as stress-induced cell cycle arrest, transcription
activation and apoptosis [53].
In G2/M-phase, BaP altered the expression of several
cell cycle regulation genes, including NPM1, PCAF,
NBN, RGC32, SESN1 and BAX as shown by Gene
Ontology and pathway analysis (Table 1 and Network
7C).N P M 1(up-regulated) has been shown to be impli-
cated in human tumourigenesis, functioning both as an
oncogene and as a tumour-suppressor. It is involved in
many pathways such as cell cycle control, DNA repair
and apoptotic response to stress by modulating the
activity and stability of critical tumour-suppressor pro-
teins such as p53 [54]. NBN (up-regulated) is involved
in cell cycle checkpoints in response to DNA damage
[55]. RGC32, SESN1 and BAX (all up-regulated) are all
targets of p53 contributing to its role in cell cycle regu-
lation, metabolism and apoptosis [56-58]. Indeed, accu-
mulation of p53 was seen after BaP treatment by
Western blotting (Figure 9).
Conclusions
Exposure of synchronized MCF-7 cells to BaP has iden-
tified a complex gene expression response by microarray
analysis. A number of genes were found to have their
expression altered by BaP, including those involved in
xenobiotic metabolism, apoptosis, cell cycle regulation
and DNA repair. Gene ontology and pathway analysis
showed the involvement of various signalling pathways
in the response to BaP, such as Catenin/Wnt pathway in
G1, ERK pathway in G1 and S, Nrf2 pathway in S and
G2/M and Akt pathway in G2/M.
A key finding in this study was that higher levels of
DNA adducts in S- and G2/M-enriched cultures corre-
lated with higher levels of CYP1A1 and CYP1B1 mRNA
and protein expression, indicating that proliferating cells
are more prone to DNA damage by genotoxic stress
than non-proliferating cells. Our results clearly demon-
strate that this is due to the varying efficiency of BaP
metabolism through the cell cycle. Additional studies
with other cells lines and genotoxic agents will be
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adduct formation and expression of CYP1A1 and
CYP1B1 (both at the mRNA and protein level) are uni-
versal or specific to certain cell types.
Methods
Cell culture and treatment
MCF-7 human breast carcinoma cells were purchased
from the European Collection of Cell Cultures (ECACC,
Salisbury, UK). Cells were grown as adherent monolayers
and maintained in Dulbecco’s modified Eagle’sm e d i u m
with Glutamax™ I, 1000 mg/L D-glucose and sodium
pyruvate (Invitrogen, Paisley, UK) and supplemented
with 10% heat-inactivated foetal bovine serum (Invitro-
gen) and 100 U/mL penicillin and 100 μg/mL streptomy-
cin (Sigma-Aldrich, Dorset, UK). Cells were incubated in
a humidified 5% CO2 atmosphere at 37°C and sub-cul-
tured every 72 h when the cells were 80% confluent.
Culture conditions were manipulated in order to gen-
erate (1) G0/G1-enriched cultures by serum deprivation
for 48 h (cells were kept in G0 by not adding the serum
back during the BaP treatement in contrast to G1-
enriched cells); (2) S-enriched cultures by serum depri-
vation for 48 h followed by 18 h growth in complete
media; and (3) G2/M-enriched cultures by treatment for
24 h with 1 μg/mL aphidicolin followed by 0.25 μM col-
chicine for 12 h. Cell cycle distributions, determined by
flow cytometry are shown in Table 3.
C e l l sw e r es e e d e da t2×1 0
5 cells/ml and treated with
BaP (2.5 μM), and BPDE (0.5 μM) for 12 hours. DMSO
only was added to control cultures and its volume was
kept at 0.3% of the total culture volume. Cells were har-
vested by trypsinisation followed by washing with PBS.
All cell incubations for the different experimental appli-
cations were carried out in duplicate or triplicate.
Flow cytometry
Harvested cells were re-suspended in 0.2 mL 10X PBS
solution and fixed in 2 mL of ice-cold 70% ethanol.
Samples were then stored at -20°C overnight. Twenty
four hours prior to flow cytometry analysis, samples
were centrifuged at 1500 × g for 5 minutes and resus-
pended in staining buffer containing 40 μg/mL propi-
dium iodide (Invitrogen), 100 μg/mL RNase (Qiagen,
UK) in PBS buffer at a final density of 1 × 10
6 cells/
mL. Cells were then incubated at 37°C for 60 minutes
a n ds t o r e da t4 ° Co v e r n i g h t .T h eD N Ac o n t e n to f
10,000 events per sample was analysed using a Beck-
man Coulter EPICS Elite ESP (Beckman Coulter, Buck-
inghamshire, UK) at 488 nm. The percentage of cells
in each phase of the cell cycle was determined using
Cylchred v1.0.2 and WinMDI v2.8 software [59]. Dif-
ferences between control and treated cells were exam-
ined for statistical significance using Student’s t-test
(two-tailed).
Cell viability
Cell viability (% control) was determined by cell count-
ing with the CASY Model TT Electronic Cell Analyser
(Innovatis AG, Germany).
DNA adduct analysis
DNA was isolated from cell pellets by a standard phenol
chloroform extraction method. DNA was quantified
spectrophotometrically and DNA adducts were deter-
mined for each DNA sample using the nuclease P1
enrichment version of
32P-postlabelling method [60].
Briefly, DNA samples (4 μg) were digested with micro-
coccal nuclease (120 mU, Sigma, UK) and calf spleen
phosphodiesterase (40 mU, Calbiochem, UK), then
enriched and labelled as reported. Solvent conditions for
the resolution of
32P-labelled adducts on polyethylenei-
mine-cellulose thin-layer chromatography (TLC) were as
described [9]. After chromatography TLC plates were
scanned using a Packard Instant Imager (Dowers Grove,
IL, USA) and DNA adduct levels (RAL, relative adduct
labelling) were calculated from the adduct cpm, the spe-
cific activity of [g-
32P]ATP and the amount of DNA
(pmol of DNA-P) used. Results were expressed as DNA
adducts/10
8 nucleotides. An external BPDE-DNA stan-
dard [61] was employed for identification of adducts in
experimental samples.
RNA isolation and whole-genome gene expression
profiling
T o t a lR N Aw a se x t r a c t e df r o mc e l l su s i n gt h eQ i a g e n
RNeasy Mini Kit protocol (RNeasy Mini Handbook,
Qiagen, UK). RNA was quantified spectrophotometri-
cally, and integrity was determined using a 2100 Bioana-
lyser (Agilent Technologies, UK). Only RNA with an
integrity number ≥ 9 was used for gene expression
analysis.
Table 3 Cell cycle distribution of MCF-7 cells prior to BaP treatment
Cell cycle distribution (%)
Culture manipulations (time, h) G0/G1-phase S-phase G2/M-phase
G0/G1-enriched 48 h serum deprivation 65.3 ± 2.1 14.1 ± 2.4 20.6 ± 2.4
S-enriched 18 h after 48 h serum deprivation 24.7 ± 4.2 55.7 ± 8.2 19.5 ± 4.0
G2/M-enriched 12 h colchicine (0.25 μM) after 24 h aphidicolin (1 μg/mL) 8.9 ± 2.2 18.2 ± 4.1 72.9 ± 5.9
Cells were manipulated to generate: G0/G1-, S-, and G2/M-enriched cultures.
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Agilent two-colour microarray-based gene expression
analysis (Agilent Technologies, UK), which uses cyanine
3 (Cy3)- and cyanine 5 (Cy5)-labelled targets to measure
gene expression in experimental and control samples.
Agilent Human 4 × 44K Genome-wide arrays were
used and the reference design was applied, whereby a
Universal Human Reference RNA (Stratagene, La Jolla,
USA) was hybridised to every sample. Cy3-(sample)-
and Cy5-(reference)-labelled probes were hybridised to
the oligo microarrays using the Gene Expression Hybri-
dization Kit (Agilent Technologies, UK) using Agilent
SureHyb chambers for 17 hours in Rotisserie Hyb Oven
set to 65°C (Agilent) and rotating at 10 rpm. The array
slides were washed according to the manufacturer’s
instructions (Agilent) and dried with compressed air
prior to scanning on an Axon B400 Scanner (Axon,
Instruments, USA).
Microarray data analysis
The multi-image TIFF files generated by the scanner
were exported to BlueFuse software, which adjusts the
initial grid position and optimises spot finding in the
image automatically so that each spot on the array is
assigned a specific gene. BlueFuse software generated
Excel files, which were analysed using GeneSpring v7.2
software (Silicon Genetics).
Data were imported into GeneSpring software and
subjected to Per chip and Per spot lowess normalisation.
Bad spots that were flagged in BlueFuse software were
filtered out in order to give a gene list of reliable data.
Cy3/Cy5 ratios of the 3 biological replicates were aver-
aged and then used to identify modulated genes using 1
W a y - A N O V Aw i t hac u t - o f fo f1 . 5 - f o l dc h a n g ea n da
Student’s t-test p-value of less than 0.05. Over-represen-
tation analysis of differentially expressed genes was car-
ried out using the Gene Ontology function within
GeneSpring and Ingenuity pathway software.
The gene expression data discussed in this publication
have been deposited in NCBI Gene Expression Omnibus
[62] and are accessible through GEO Series accession
number GSE26917.
Real-time quantitative PCR
Two-step reverse transcription-PCR was used to generate
cDNA for relative quantitation analysis using real-time
fluorescent PCR. cDNA was reversed transcribed from 1
μg total RNA using random primers following the Super-
script III Reverse Transcriptase First-Strand cDNA
Synthesis Protocol (Invitrogen). cDNA was diluted 1:10
and 2 μL was used as template to perform RT-PCR in a
15 μL reaction. GAPDH was used as an endogenous con-
trol (Applied Biosystems, UK) in multiplexed PCR reac-
tions on an ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems) with standard thermocy-
cling conditions (50°C 2 min, 95°C 10 min, then 40 cycles
of 95°C 15 s, 60°C 1 min), using Taqman Universal PCR
Master Mix (Applied Biosystems). To confirm the modu-
lated expression of the selected target genes, 20x Assays-
On-Demand™ gene expression primers and probes
(Applied Biosystems) were used. The list of the assays is
provided as Additional file 8. Relative gene expression
between the control (or calibrator) and treated samples
was calculated after normalisation to the GAPDH refer-
ence using the comparative threshold cycle (CT) method.
Western blot analysis
Cells were lysed in 800 μL lysis buffer (62.5 mM Tris
pH 6.8, 1 mM EDTA pH 8.0, 2% SDS, 10% Glycerol).
Samples were sonicated to break up the DNA and their
protein concentration was determined using the BCA
assay (Piercenet, UK) in order to load the same amounts
of protein. Cell lysates were electrophoretically separated
using Criterion XT 4-12% Bis-Tris gels (Bio-Rad, UK).
Following electrophoresis, gels were transferred onto a
nitrocellulose membrane (Millipore, UK). Ponceau stain-
ing was performed to check for the quality of transfer,
and then the membranes were blocked by incubation in
5% non-fat dry milk dissolved in TBST overnight at 4°C.
Blots were then incubated with primary antibody, there-
after with the species-specific horseradish peroxidase-
conjugated secondary antibody and bands detected by
chemiluminescence (ECL detection reagents, GE Health-
care). The following primary antibodies were purchases:
anti-p53 (Ab-6; 1:2,000) from Calbiochem (Darmstadt,
Germany), anti-p21 (BD 556431; 1:2,000) from BD
Science (Oxford, UK), anti-CYP1B1 (CYP1B11-A;
1:2,000) from Alpha Diagnostic (Hampshire, UK), anti-
AHR (Abcam ab2770; 1:1,000). Anti-CYP1A1 raised in
rabbits against purified human recombinant CYP1A1
was a generous gift from F. Peter Guengerich (Vander-
bilt University, USA) and was diluted 1:4,000. The anti-
body to detect b-actin (Ab6276; 1:25,000) was
p u r c h a s e df r o mA b c a ma n du s e da sal o a d i n gc o n t r o l .
Two secondary horseradish peroxidise-linked antibodies
were purchased: anti-mouse (CST 7076; 1:10,000), anti-
rabbit (CST 7074; 1:10,000) from Cell Signalling Tech-
nologies (Herts, UK). Band quantification was carried
out using ImageJ software [63].
Additional material
Additional file 1: BaP delays escape from S-phase (Histogram
representation). A- MCF-7 cells were synchronised in G0/G1-phase by
serum-deprivation for 48 h, after which cells were exposed for 12 h to
BaP (2.5 μM) or DMSO. B- MCF-7 cells were enriched in S-phase by
serum-deprivation for 48 h, then left to grow for 18 h, after which they
were treated by either BaP (2.5 μM) or DMSO for 12 h. C- MCF-7 cells
were synchronised in G2/M-phase by exposing them to aphidicolin (1
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Page 14 of 16μg/mL) for 24 h followed by colchicine (0.25 μM) for 12 h. Subsequently,
they were released into media containing either BaP (2.5 μM) or DMSO
for 12 h. Cell cycle distribution was examined by flow cytometry and
DNA histograms were generated. The profiles are representative of three
independent experiments.
Additional file 2: List of differentially-expressed genes common to
G1-, S- and G2/M-enriched cultures after 12h BaP (2.5 μM)
treatment. Only genes which had a change of 1.5-fold after BaP
exposure are shown.
Additional file 3: List of differentially-expressed genes common to
G1- and S-enriched cultures only after 12h BaP (2.5 μM) treatment.
Only genes which had a change of 1.5-fold after BaP exposure are
shown.
Additional file 4: List of differentially-expressed genes common to
G1- and G2/M-enriched cultures only after 12h BaP (2.5 μM)
treatment. Only genes which had a change of 1.5-fold after BaP
exposure are shown.
Additional file 5: List of differentially-expressed genes common to
S- and G2/M-enriched cultures only after 12h BaP (2.5 μM)
treatment. Only genes which had a change of 1.5-fold after BaP
exposure are shown.
Additional file 6: Ingenuity pathway analysis (IPA) figures legend.
Additional file 7: List of the top five scoring network in each
enriched culture. Scores are obtained within Ingenuity pathway analysis
(IPA) software.
Additional file 8: Gene expression primers and probes used in RT-
PCR reactions. The assays were purchased from Applied Biosystems and
each consists of 2 primers (forward and reverse) and a Taqman probe.
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